Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease

Journal of Thoracic Disease

Volumn 9, Issue 2, 2017, Pages 362-371

  Yamakawa, Hideaki ^a,b   Hagiwara, Eri ^a   Kitamura, Hideya ^a,b   Yamanaka, Yumie ^a,b   Ikeda, Satoshi ^a   Sekine, Akimasa ^a   Baba, Tomohisa ^a   Okudela, Koji ^c   Iwasawa, Tae ^a   Takemura, Tamiko ^d   Kuwano, Kazuyoshi ^b   Ogura, Takashi ^a  

^a Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center Hospital   (Japan)

^b JIKEI UNIVERSITY HOSPITAL   (Japan)

^c YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d JAPANESE RED CROSS MEDICAL CENTER   (Japan)

Author keywords

Biomarker; Interstitial lung disease (ILD); Mixed connective tissue disease (MCTD); Systemic sclerosis (SSc)

Indexed keywords

BIOLOGICAL MARKER; CARBON MONOXIDE; KREBS VON DEN LUNGEN 6; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MALE; MEDICAL RECORD REVIEW; MIXED CONNECTIVE TISSUE DISEASE; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; SYSTEMIC SCLEROSIS;

EID: 85014115613     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.21037/jtd.2017.02.48     Document Type: Article

References (33)

1. Silver RM. Scleroderma. Clinical problems. The lungs. Rheum Dis Clin North Am 1996;22:825-40.
2. Hasegawa M, Asano Y, Endo H, et al. Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: a multicentre prospective observational study. Rheumatology (Oxford) 2012;51:129-33.
3. Fagundes MN, Caleiro MT, Navarro-Rodriguez T, et al. Esophageal involvement and interstitial lung disease in mixed connective tissue disease. Respir Med 2009;103:854-60.
4. Smolen JS, Steiner G. Mixed connective tissue disease: to be or not to be? Arthritis Rheum 1998;41:768-77.
5. Hoffmann-Vold AM, Aaløkken TM, Lund MB, et al. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheumatol 2015;67:2205-12.
6. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
7. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70.
8. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613-9.
9. Gunnarsson R, Hetlevik SO, Lilleby V, et al. Mixed connective tissue disease. Best Pract Res Clin Rheumatol 2016;30:95-111.
10. Kohno N, Kyoizumi S, Awaya Y, et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989;96:68-73.
11. Takahashi H, Kuroki Y, Tanaka H, et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 2000;162:258-63.
12. Sakamoto K, Taniguchi H, Kondoh Y, et al. Serum KL-6 in fibrotic NSIP: Correlations with physiologic and radiologic parameters. Respir Med 2010;104:127-33.
13. Okada F, Ando Y, Honda K, et al. Comparison of pulmonary CT findings and serum KL-6 levels in patients with cryptogenic organizing pneumonia. Br J Radiol 2009;82:212-8.
14. Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 2014;146:422-36.
15. Yamakawa H, Hagiwara E, Kitamura H, et al. Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis. PLoS One 2016;11:e0161908.
16. Asano Y, Ihn H, Yamane K, et al. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum 2001;44:1363-9.
17. Yanaba K, Hasegawa M, Hamaguchi Y, et al. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. Clin Exp Rheumatol 2003;21:429-36.
18. Yanaba K, Hasegawa M, Takehara K, et al. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004;31:1112-20.
19. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737-47.
20. Sharp GC, Irvin WS, May CM, et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. N Engl J Med 1976;295:1149-54.
21. Cappelli S, Bellando Randone S, et al. "To be or not to be, " ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum 2012;41:589-98.
22. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
23. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733-48.
24. Iwasawa T, Kato S, Ogura T, et al. Low-normal lung volume correlates with pulmonary hypertension in fibrotic idiopathic interstitial pneumonia: computer-aided 3D quantitative analysis of chest CT. AJR Am J Roentgenol 2014;203:W166-73.
25. Iwasawa T, Kanauchi T, Hoshi T, et al. Multicenter study of quantitative computed tomography analysis using a computer-aided three-dimensional system in patients with idiopathic pulmonary fibrosis. Jpn J Radiol 2016;34:16-27.
26. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J 2005;47:458-72.
27. Yamane K, Ihn H, Kubo M, et al. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol 2000;27:930-4.
28. Bonella F, Volpe A, Caramaschi P, et al. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis 2011;28:27-33.
29. Saketkoo LA, Mittoo S, Huscher D, et al. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax 2014;69:428-36.
30. Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-9.
31. Wells AU. Interstitial lung disease in systemic sclerosis. Presse Med 2014;43:e329-43.
32. Nimelstein SH, Brody S, McShane D, et al. Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine (Baltimore) 1980;59:239-48.
33. Aringer M, Steiner G, Smolen JS. Does mixed connective tissue disease exist? Yes. Rheum Dis Clin North Am 2005;31:411-20, v.